Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Narcolepsy01:07

Narcolepsy

137
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
137
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

248
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
248
Management of Insomnia01:19

Management of Insomnia

278
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
278
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

196
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
196
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

200
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric obstructive sleep apnea hypopnea diagnosis using a video recording score: A pilot study.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.

BMJ case reports·2025
Same author

Screening for impaired alertness and accidental risk with Epworth Sleepiness Scale in patients with obstructive sleep apnea treated with CPAP.

Sleep medicine·2025
Same author

Two-meshes approach in posterior component separation with transversus abdominis release: the IMPACT study (Italian Multicentric Posterior-separation Abdominal Complex hernia Transversus-release).

Hernia : the journal of hernias and abdominal wall surgery·2024
Same author

Editorial.

Revue neurologique·2023
Same author

Restless legs syndrome: From clinic to personalized medicine.

Revue neurologique·2023
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice
08:44

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice

Published on: February 21, 2021

4.4K

Narcolepsies, update in 2023.

L Barateau1, F Pizza2, S Chenini1

  • 1Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU de Montpellier, Montpellier, France; National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Montpellier, France; Institute of Neurosciences of Montpellier, University of Montpellier, Inserm, Montpellier, France.

Revue Neurologique
|August 27, 2023
PubMed
Summary
This summary is machine-generated.

Narcolepsy type 1 (NT1) is caused by orexin neuron loss, diagnosed via cerebrospinal fluid hypocretin-1/orexin-A levels. New diagnostic criteria and upcoming orexin receptor agonists offer improved management for narcolepsy.

Keywords:
CataplexyMultiple sleep latency testNarcolepsy type 1Narcolepsy type 2Orexin/hypocretinSleep onset REM period

More Related Videos

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.8K
Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice
10:56

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice

Published on: August 2, 2017

10.1K

Related Experiment Videos

Last Updated: Jul 18, 2025

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice
08:44

Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice

Published on: February 21, 2021

4.4K
Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

9.8K
Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice
10:56

Quantifying Infra-slow Dynamics of Spectral Power and Heart Rate in Sleeping Mice

Published on: August 2, 2017

10.1K

Area of Science:

  • Neuroscience
  • Sleep Medicine
  • Endocrinology

Background:

  • Narcolepsy types 1 (NT1) and 2 (NT2) are distinct sleep disorders with recent scientific advancements.
  • NT1 pathogenesis involves the loss of orexin/hypocretin-producing hypothalamic neurons, crucial for wake regulation.
  • Orexin deficiency underlies key NT1 symptoms: excessive daytime sleepiness, cataplexy, disrupted sleep, hallucinations, and paralysis.

Purpose of the Study:

  • To review diagnostic criteria and biomarkers for narcolepsy types 1 and 2.
  • To discuss the role of hypocretin-1/orexin-A in NT1 diagnosis.
  • To explore clinical features, diagnostic challenges, and future therapeutic strategies for narcolepsy.

Main Methods:

  • Analysis of cerebrospinal fluid (CSF) hypocretin-1/orexin-A levels as a diagnostic biomarker for NT1.
  • Review of neurophysiological tests (polysomnography, multiple sleep latency test) and clinical criteria for narcolepsy diagnosis.
  • Examination of the revised International Classification of Sleep Disorders, 3rd edition (ICSD-3-TR) diagnostic guidelines.

Main Results:

  • Low CSF hypocretin-1/orexin-A is a highly specific and sensitive biomarker for diagnosing NT1.
  • The ICSD-3-TR updated diagnostic criteria, allowing sleep onset REM periods (SOREMPs) to replace diurnal tests in specific cases.
  • Cataplexy diagnosis relies heavily on clinical interview, with proposed features for typical and atypical attacks.

Conclusions:

  • Orexin deficiency is the definitive cause of NT1, with CSF hypocretin-1/orexin-A as a key diagnostic marker.
  • NT2 diagnosis remains challenging due to unknown etiology and lack of specific biomarkers.
  • Symptomatic treatment is current standard, but orexin receptor agonists promise revolutionary therapeutic advancements for narcolepsy.